BOSTON, Oct. 6, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company is proud to support the National Breast Cancer Foundation (NBCF) by donating 5% of its sales from the MammoView® Breast Endoscopy Instrument line for the month of October to the NBCF. Solos currently sells instruments from its MammoView® line to hospitals across the Country through direct sales channels and social media.
MammoView® Instrument line contains 13 different Breast Endoscopy Components which are all featured on the Company’s website http://www.solosendoscopy.com/newproductline.html.
The Solos MammoView®Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of the breast cancers arise. Solos’ intraductal devices are designed to provide direct observation with any endoscopic video system while providing unprecedented image quality, using advanced minimally invasive technologies and tissue preservation techniques.
The National Breast Cancer Foundation (NBCF) is committed to spreading knowledge and fostering hope in the fight against breast cancer. By funding free mammograms for women who could otherwise not afford them and supporting research programs in leading facilities across the country, NBCF helps inspire the courage needed to win this monumental battle. The National Breast Cancer Foundation mission is to save lives through early detection and to provide mammograms for those in need. Their mission includes increasing awareness through education, providing diagnostic breast care services for those in need, and providing nurturing support services.
The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
“We are committed to supporting organizations such as the National Breast Cancer Foundation. We share their mission that early detection is the key to saving lives,” stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
For more information on The National Breast Cancer Foundation (NBCF) please visit www.nationalbreastcancer.org.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact:
Amanda Segersten,
Rsegersten@solosendoscopy.com
SOURCE Solos Endoscopy, Inc.
